| Size | Price | Stock | Qty |
|---|---|---|---|
| 500mg |
|
||
| Other Sizes |
| Targets |
Kojic acid dipalmitate targets tyrosinase, the key enzyme in melanin biosynthesis. It is a slow and reversible competitive inhibitor of tyrosinase. By inhibiting tyrosinase, the compound prevents melanin synthesis. Kojic acid is also a slow-binding inhibitor of the catecholase activity of tyrosinase with a Ki of 2.75 µM.
|
|---|---|
| ln Vitro |
Tyrosinase activity in the skin is effectively inhibited by kojic acid dipalmitate, which prevents the synthesis of melanin. Compared to kojic acid, kojic acid dipalmitate is more efficient[1].
Kojic acid dipalmitate demonstrates potent in vitro tyrosinase inhibitory activity. It effectively inhibits tyrosinase activity in the skin, preventing the synthesis of melanin. Kojic acid dipalmitate is more efficient than kojic acid. It is a slow and reversible competitive inhibitor of tyrosinase. |
| ln Vivo |
In vivo activity data for Kojic acid dipalmitate are not extensively documented. Its use as a skin-lightening agent in cosmetics suggests that it is effective in vivo. Its lipophilic nature may enhance skin penetration compared to kojic acid. Further in vivo studies are needed to fully characterize its efficacy and pharmacokinetic profile.
|
| Enzyme Assay |
The in vitro enzyme assay for Kojic acid dipalmitate involves measuring its inhibition of tyrosinase activity. Mushroom tyrosinase is commonly used as a model enzyme. The assay typically uses L-DOPA as a substrate, and the formation of dopachrome is monitored spectrophotometrically at 475 nm. Kojic acid dipalmitate is incubated with the enzyme and substrate at various concentrations. The IC50 or Ki value is determined by fitting the inhibition data to a dose-response curve.
|
| Cell Assay |
In vitro cellular assays for Kojic acid dipalmitate typically use B16 melanoma cells or human melanocytes to assess its effects on melanogenesis. Cells are treated with the compound at various concentrations. Melanin content is measured spectrophotometrically. Tyrosinase activity is assessed by measuring the oxidation of L-DOPA in cell lysates. The compound's ability to reduce melanin production is quantified.
|
| Animal Protocol |
In vivo animal experiments for Kojic acid dipalmitate are not extensively documented. As a skin-lightening agent, standard in vivo studies would involve animal models of hyperpigmentation. The compound would be administered via topical routes. Melanin content in skin and histopathological analysis would be assessed.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Kojic acid dipalmitate are not extensively documented. As a lipophilic ester, it is expected to have better skin penetration than kojic acid. Its metabolism would involve hydrolysis to release kojic acid and palmitic acid. Further pharmacokinetic studies are necessary to fully characterize its absorption, distribution, metabolism, and excretion.
|
| Toxicity/Toxicokinetics |
Toxicological data for Kojic acid dipalmitate are not extensively available. As a cosmetic ingredient, it is generally considered safe for topical use. Kojic acid has been evaluated for safety in cosmetic products. Further toxicological studies would be required for systemic use.
|
| References | |
| Additional Infomation |
Kojic acid dipalmitate is a lipophilic ester derivative of kojic acid that acts as a slow and reversible competitive inhibitor of tyrosinase. It effectively inhibits melanin synthesis and is more efficient than kojic acid. The compound is used as a skin-lightening agent in research. No clinical trials or regulatory approvals have been reported.
|
| Molecular Formula |
C38H66O6
|
|---|---|
| Molecular Weight |
618.93
|
| Exact Mass |
618.485
|
| CAS # |
79725-98-7
|
| PubChem CID |
71587292
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Boiling Point |
684.7±55.0 °C at 760 mmHg
|
| Melting Point |
92-96ºC
|
| Flash Point |
273.9±31.5 °C
|
| Vapour Pressure |
0.0±2.1 mmHg at 25°C
|
| Index of Refraction |
1.492
|
| LogP |
15.3
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
43
|
| Complexity |
784
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCCCCCCCCCCCCC(=O)OCC1=CC(=O)C(=CO1)OC(=O)CCCCCCCCCCCCCCC
|
| InChi Key |
URJOWNUVTORLNY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C37H64O6/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-35(39)42-34-32-41-37(31-33(34)38)43-36(40)30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h31-32H,3-30H2,1-2H3
|
| Chemical Name |
(5-hexadecanoyloxy-4-oxopyran-2-yl) hexadecanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6157 mL | 8.0785 mL | 16.1569 mL | |
| 5 mM | 0.3231 mL | 1.6157 mL | 3.2314 mL | |
| 10 mM | 0.1616 mL | 0.8078 mL | 1.6157 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
